The U.S. Food and Drug Administration (FDA) has expanded approval for Omisirge (omidubicel-onlv) to treat severe aplastic anemia in children aged 6 years and older. Omisirge was previously approved for patients aged 12 and older with blood cancers This new approval provides a vital hematopoietic stem cell transplant (HSCT) therapy option for patients who do not have a compatible donor, addressing a critical need in pediatric care.
What Is Omisirge?
Omisirge is an advanced stem cell therapy, created from enhanced umbilical cord blood. The therapy uses nicotinamide, a vitamin B3 derivative, to improve the expansion and engraftment of stem cells. By boosting the number and quality of transplanted stem cells, Omisirge enables more effective umbilical cord blood transplants and offers an alternative for patients without a matched donor.
Understanding Severe Aplastic Anemia
Severe aplastic anemia is a rare bone marrow failure disorder in which the body cannot produce adequate red blood cells, white blood cells, or platelets. Patients are at high risk for fatigue, infections, and bleeding complications.
Standard SAA treatment options include immunosuppressive therapy and hematopoietic stem cell transplant.
Details of the FDA Expansion
The FDA’s updated approval for Omisirge covers:
- Children aged 6 years and older and adults with severe aplastic anemia
- Patients without a compatible stem cell donor
- Use following reduced-intensity conditioning regimens
Clinical Trial Evidence Supporting Omisirge
The expanded FDA approval is supported by ongoing clinical research in patients aged 6 and above. In a single-arm, prospective study, Omisirge demonstrated early appearance and maintenance of neutrophils in the blood of 12 out of 14 patients, with a median recovery time of 11 days (range 7–20).
These results indicate that Omisirge not only enables faster immune recovery but also reduces the risk of infections after transplant, making it an effective stem cell therapy for severe aplastic anemia in children.
Safety Profile of Omisirge
As with other HSCT therapies, Omisirge has associated risks. Common adverse effects observed in clinical studies include:
- Febrile neutropenia
- Viral and bacterial infections
- Hyperglycemia
- Immune thrombocytopenia
- Pneumonia
- Autoimmune cytopenias
Why the FDA Approval Matters
This FDA decision expands treatment possibilities for children with severe aplastic anemia, particularly those without a matched donor. Omisirge offers:
- A new stem cell transplant option that improves neutrophil recovery
- An alternative to traditional umbilical cord blood transplants, which may have slower engraftment and higher infection risks
- Increased access to effective HSCT therapy for pediatric patients
References: